Breast cancer prognosis is steadily improving due to early detection of primary cancer in
screening programs and revolutionizing treatment development. In the metastatic setting …

While current international guidelines include imaging of the target lesion for response
monitoring in metastatic breast cancer, they do not provide specific recommendations for …

Purpose The aim of this study was to compare fluorodeoxyglucose positron emission
tomography/computed tomography (FDG PET/CT) and contrast-enhanced computed …

This study aimed to compare CE-CT and 2-[18F] FDG-PET/CT for response monitoring
metastatic breast cancer (MBC). The primary objective was to predict progression-free and …

This study aimed to compare contrast-enhanced CT (CE-CT) and 18F-FDG PET/CT for
response monitoring in metastatic breast cancer using the standardized response …

The PET Response Criteria in Solid Tumors (PERCIST) are not specific regarding the
number of lesions that should be analyzed per patient. This study evaluated how the number …

OBJECTIVE. FDG PET/CT affects the management of patients with breast cancer in multiple
settings, including initial staging, treatment response assessment, and evaluation of …

Response evaluation at regular intervals is indicated for treatment of metastatic breast
cancer (MBC). FDG-PET/CT has the potential to monitor treatment response accurately. Our …

Background: We aimed to examine the feasibility and potential benefit of applying PET
Response Criteria in Solid Tumors (PERCIST) for response monitoring in metastatic breast …

Chemotherapy is currently the treatment of choice for patients with high-risk metastatic
breast cancer. Clinical response is determined after several cycles of chemotherapy by …